Frequency Therapeutics, Inc. FREQ
We take great care to ensure that the data presented and summarized in this overview for Frequency Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in FREQ
Top Purchases
Top Sells
About FREQ
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Insider Transactions at FREQ
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Vineet Agarwal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
800
-100.0%
|
$56,000
$70.0 P/Share
|
|
Nov 11
2024
|
Vineet Agarwal Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+50.0%
|
$8,800
$11.68 P/Share
|
|
Oct 17
2024
|
Vineet Agarwal Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,216
-31.39%
|
$786,632
$77.6 P/Share
|
|
Oct 17
2024
|
Vineet Agarwal Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,216
+29.27%
|
$132,808
$13.33 P/Share
|
|
Apr 22
2024
|
Scott D Sandell |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Mohamad Makhzoumi |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Rick Yang |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Edward T Mathers |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Carmen Chang |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Paul Edward Walker |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Anthony A. Florence Jr. |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Forest Baskett |
BUY
Open market or private purchase
|
Indirect |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
New Enterprise Associates 17, L.P. |
BUY
Open market or private purchase
|
Direct |
17,857
+1.61%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Jean Francois Formela |
BUY
Grant, award, or other acquisition
|
Indirect |
17,857
+8.39%
|
$999,992
$56.0 P/Share
|
|
Apr 22
2024
|
Atlas Venture Opportunity Fund Ii, L.P. |
BUY
Open market or private purchase
|
Direct |
17,857
+8.39%
|
$999,992
$56.0 P/Share
|
|
Nov 22
2023
|
David L. Lucchino |
SELL
Open market or private sale
|
Direct |
1,156
-1.26%
|
$42,772
$37.38 P/Share
|
|
Nov 10
2023
|
David L. Lucchino |
SELL
Open market or private sale
|
Direct |
968
-0.58%
|
$40,656
$42.63 P/Share
|
|
Nov 03
2023
|
David L. Lucchino |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+19.82%
|
-
|
|
Nov 03
2023
|
David L. Lucchino |
BUY
Exercise of conversion of derivative security
|
Direct |
5,600
+23.46%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 179K shares |
|---|---|
| Grant, award, or other acquisition | 35.7K shares |
| Exercise of conversion of derivative security | 11K shares |
| Open market or private sale | 11K shares |
|---|